Diapin

Diapin is an orally active tripeptide drug candidate composed of three natural L-amino acids (Gly-Gly-Leu) that has been investigated preclinically for the treatment of type 2 diabetes. In rodent models of obesity and diabetes, oral administration of Diapin lowers postprandial blood glucose, improves glucose tolerance, and reduces casual blood glucose without causing hypoglycemia, effects associated with increased circulating levels of glucagon-like peptide-1 (GLP-1) and insulin.[1][8] Mechanistically, Diapin appears to act on enteroendocrine L‑cells in the gastrointestinal tract to stimulate GLP‑1 secretion, which in turn enhances glucose‑dependent insulin secretion from pancreatic β‑cells, and may also directly stimulate insulin release from β‑cells, together improving glucose homeostasis.[1][8] The peptide was originally developed through academic research at the University of Michigan and further advanced by Diapin Therapeutics, but available data indicate it remains at an early, preclinical stage without human efficacy data.[1][7][8]